Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. USO
2. DHR
3. NVDA
4. SPY
5. AMD
6. NOW
7. GM
8. SMCI
9. GOOGL
10. IBM

Go back to Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush

June 29, 2026 12:25 PM EDT

Wedbush analyst Laura Chico raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $43.00 (from $32.00) while maintaining a Outperform rating.

The analyst comments "Remain Outperform rated on VRDN, new $43 target. Most notable on the VRDN investor call, management confirmed the Lumvoa price... More

William Blair on Viridian Therapeutic (VRDN): 'We came away from the call incrementally more confident'

June 29, 2026 12:25 PM EDT

William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Viridian Therapeutic (NASDAQ: VRDN)

The analyst comments "On Monday, June 29, Viridian hosted a call to discuss the approval and commercial launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED).... More